

Clinical trials of saxagliptin + glyburide

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
saxagliptin + glyburide vs glyburide uptitration			
CV181-040 [NCT00313313] n=NA follow-up: 24 weeks	saxagliptin added to a submaximal sulphonylurea dose versus uptitration of sulphonylurea monotherapy	patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy	

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

References

CV181-040, :

Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. *Int J Clin Pract* 2009 Sep;63:1395-406 [[19614786](#)]

Chacra AR, Tan GH, Ravichandran S, List J, Chen R Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. *Diab Vasc Dis Res* 2011;8:150-9 [[21562067](#)] [10.1177/1479164111404574](https://doi.org/10.1177/1479164111404574)

Entry terms: saxagliptin, saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118,